WO1994004159A3 - Traitement du cancer a l'azt ou a l'aide d'agents d'alkylation ou de chelation - Google Patents

Traitement du cancer a l'azt ou a l'aide d'agents d'alkylation ou de chelation Download PDF

Info

Publication number
WO1994004159A3
WO1994004159A3 PCT/GB1993/001789 GB9301789W WO9404159A3 WO 1994004159 A3 WO1994004159 A3 WO 1994004159A3 GB 9301789 W GB9301789 W GB 9301789W WO 9404159 A3 WO9404159 A3 WO 9404159A3
Authority
WO
WIPO (PCT)
Prior art keywords
azt
alkylating
cancer
treatment
intercalating agents
Prior art date
Application number
PCT/GB1993/001789
Other languages
English (en)
Other versions
WO1994004159A2 (fr
Inventor
Bangaru Chandrasekaran
David Stanley Duch
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Priority to EP93919464A priority Critical patent/EP0655918A1/fr
Priority to JP6506072A priority patent/JPH08500356A/ja
Priority to AU49679/93A priority patent/AU4967993A/en
Publication of WO1994004159A2 publication Critical patent/WO1994004159A2/fr
Publication of WO1994004159A3 publication Critical patent/WO1994004159A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

L'invention concerne des procédés de traitement du cancer chez un mammifère qui consistent à administrer audit mammifère une dose efficace de potentialisation d'AZT, un sel ou un ester pharmaceutiquement acceptable de cette dernière, combinée à une dose efficace d'un agent d'alkylation ou un agent intercalant d'ADN. L'agent d'alkylation préféré est le melphalan et l'agent intercalant d'ADN l'adriamycine.
PCT/GB1993/001789 1992-08-24 1993-08-23 Traitement du cancer a l'azt ou a l'aide d'agents d'alkylation ou de chelation WO1994004159A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP93919464A EP0655918A1 (fr) 1992-08-24 1993-08-23 Traitement du cancer a l'azt ou a l'aide d'agents d'alkylation ou de chelation
JP6506072A JPH08500356A (ja) 1992-08-24 1993-08-23 Ａｚｔおよびアルキル化剤または挿入剤による癌の処置
AU49679/93A AU4967993A (en) 1992-08-24 1993-08-23 Treatment of cancer with azt and alkylating or intercalating agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929217998A GB9217998D0 (en) 1992-08-24 1992-08-24 Methods of treating cancer
GB9217998.5 1992-08-24

Publications (2)

Publication Number Publication Date
WO1994004159A2 WO1994004159A2 (fr) 1994-03-03
WO1994004159A3 true WO1994004159A3 (fr) 1994-04-14

Family

ID=10720879

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1993/001789 WO1994004159A2 (fr) 1992-08-24 1993-08-23 Traitement du cancer a l'azt ou a l'aide d'agents d'alkylation ou de chelation

Country Status (8)

Country Link
EP (1) EP0655918A1 (fr)
JP (1) JPH08500356A (fr)
AU (1) AU4967993A (fr)
GB (1) GB9217998D0 (fr)
IL (1) IL106763A0 (fr)
MX (1) MX9305106A (fr)
WO (1) WO1994004159A2 (fr)
ZA (1) ZA936166B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6338843B1 (en) * 1997-06-12 2002-01-15 Ml Laboratories Biologically active materials
US20080261913A1 (en) * 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
BR112013003658B1 (pt) * 2010-07-28 2022-02-22 Life Technologies Corporation Composição farmacêutica compreendendo ácido graxo, carboidrato e lipídio de isoprenoide modificados com azida, uso de tais componentes e método para inibir infectividade de um vírus
US20180110780A1 (en) * 2015-04-30 2018-04-26 Taiho Pharmaceutical Co., Ltd. Agent for alleviating side effect of antitumor drug
CN110418840A (zh) * 2017-01-23 2019-11-05 健康研究股份有限公司 用于预防和治疗癌症与衰老的内源性逆转录酶抑制和细胞靶向

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3821676A1 (de) * 1988-06-28 1990-02-08 Werner E G Prof Dr Mueller Verwendung von avaron oder avaron-derivaten in kombination mit 3'-azido-3'-deoxythymidin zur antiviralen therapie
US5116823A (en) * 1990-02-27 1992-05-26 Roger Williams General Hospital Drug combinations containing AZT

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3821676A1 (de) * 1988-06-28 1990-02-08 Werner E G Prof Dr Mueller Verwendung von avaron oder avaron-derivaten in kombination mit 3'-azido-3'-deoxythymidin zur antiviralen therapie
US5116823A (en) * 1990-02-27 1992-05-26 Roger Williams General Hospital Drug combinations containing AZT

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
A.M. LEVINE: "Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma.", JAMA, vol. 266, no. 1, 1991, pages 84 - 88 *
CANCER RES, 1987, 47 (24 PT 1):6565-71 *
DIALOG INFORMATION SERVICES, INC. FILE 155, MEDLINE. AN=06407641 *
DIALOG INFORMATION SERVICES, INC. FILE 155, MEDLINE. AN=07369260 *
DRUGS, 1990, 39 (4):489-501 *
G. TORLONTANO: "AIDS-related complex treated by antiviral drugs and allogeneic bone marrow transplantation following conditioning protocol with busulfan, cyclophosphamide and cyclosporin.", HAEMATOLOGICA, vol. 77, no. 3, June 1992 (1992-06-01), pages 287 - 290 *
G. WEBER: "Azidothymidine inhibition of thymidine kinase and synergistic cytotoxicity with methotrexate and 5-fluorouracil in rat hepatoma and human comlon cancer cells.", CANCER COMMUN., vol. 2, no. 4, 1990, pages 129 - 133 *
G. WEBER: "AZT: a biochemical response modifier of methotrexate and 5-fluorouracil cytotoxicity in human ovarian and pancreatic carcinoma cells.", CANCER COMMUN., vol. 3, no. 4, 1991, pages 127 - 132 *
GOODMAN GILMAN, A. ET AL. (EDS.), 'GOODMAN AND GILMAN'S THE PHARMACOLOGICAL BASIS OF THERAPEUTICS', 7TH EDITION, 1985, MACMILLAN PUBLISHING COMPANY,, NEW YORK. *
I. BRUNETTI: "5-Fluorouracil enhances azidothymidine cytotoxicity: in vitro, in vivo, and biochemical studies.", CANCER RES., vol. 50, no. 13, 1990, pages 4026 - 4031 *
K.J. SCANLON: "Overexpression of DNA replication and repair enzymes in cisplatin-resistant human colon carcinoma HCT8 cells and circumvention by azidothymidine.", CANCER COMMUN., vol. 1, no. 4, 1989, pages 269 - 275 *
M.R. POSNER: "Oral zidovudine, continuous-infusion fluouracil, and oral leucovorin calcium: a phase I study.", J. NATL. CANCER INST., vol. 82, no. 21, 1990, pages 1710 - 1714 *
P. TOSI: "Azidothymidine-induced cytotoxicity and incorporation into DNA in the human colon tumor cell line HCT-8 is enhanced by methotrexate in vitro and in vivo.", CANCER RES., vol. 52, no. 15, 1 August 1992 (1992-08-01), pages 4069 - 4073 *

Also Published As

Publication number Publication date
EP0655918A1 (fr) 1995-06-07
JPH08500356A (ja) 1996-01-16
WO1994004159A2 (fr) 1994-03-03
GB9217998D0 (en) 1992-10-07
ZA936166B (en) 1995-02-23
IL106763A0 (en) 1993-12-08
MX9305106A (es) 1994-03-31
AU4967993A (en) 1994-03-15

Similar Documents

Publication Publication Date Title
WO1997044063A3 (fr) Conjugues d'acide cis-docosahexanoïque et d'agents pharmaceutiques
CA2370030A1 (fr) Composition de blocage du canal sodique et leur utilisation
WO2000038665A3 (fr) Techniques permettant d'utiliser un antagoniste de l'integrine et un ou plusieurs agents antineoplasiques comme therapie combinee pour traiter les maladies neoplasiques
MY119375A (en) Treatment of tinnitus using neuroprotective agents
HUT76258A (en) Compositions comprising dna damaging agents and p53, and methods for uses thereof
AU7720496A (en) The use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
EP0935963A3 (fr) Utilisation des inhibiteurs selectifs de MMP-13 pour le traitement de l'osteoarthrite et autres maladies mediées par le matrix metalloproteinase
CA2311356A1 (fr) Procede pour le traitement de la maladie d'alzheimer
PL310476A1 (en) Application of lamotrigin in treating neuro-aids diseases
WO1998030242A3 (fr) Compositions photochimiotherapeutiques
WO2001093909A3 (fr) Procede de traitement du cancer
WO1997005870A3 (fr) Emploi de griseofulvine pour inhiber la croissance des cancers
CA2281807A1 (fr) Methode de traitement d'une tumeur
CA2254682A1 (fr) Methode de traitement d'infections oculaires au moyen d'azithromycine
CA2275167A1 (fr) Utilisation locale d'agonistes opioides kappa dans le traitement de la douleur oculaire
GB9709360D0 (en) Methods for the treatment of herpes virus infections
MY118986A (en) Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
WO2000013712A3 (fr) Methodes et compositions pour la prevention ou le traitement du cancer
WO1994004159A3 (fr) Traitement du cancer a l'azt ou a l'aide d'agents d'alkylation ou de chelation
ZA972601B (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
EP0744176A3 (fr) Médicaments pour inhiber les pertes osseuses
TW370461B (en) Use of cross-linked hemoglobin in treating subarachnoid hemorrhage
WO1998042650A3 (fr) Antagonistes de leucotriene utilises dans le traitement de la mucoviscidose
CA2129043A1 (fr) Emploi de la 3,5-diamino-6-(2,3-dichlorophenyle)-1,2,4-triazine pour le traitement de la douleur et de l'oedeme
EP1234585A3 (fr) Compositions pour la prévention ou le traitement du cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BG BR CA CZ FI HU JP KR NO NZ PL RO RU SK UA US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BG BR CA CZ FI HU JP KR NO NZ PL RO RU SK UA US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1993919464

Country of ref document: EP

ENP Entry into the national phase

Ref country code: US

Ref document number: 1995 387830

Date of ref document: 19950406

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1993919464

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1993919464

Country of ref document: EP